Sandoz Unveils $400m+ Investment In Slovenian Biosimilars Plant
Lendava Biologics Facility Is Expected To Become Fully Operational By 2026
Spurred on by “increasing global demand for biosimilar medicines,” Sandoz has revealed plans to invest at least $400m in building a new biologics production plant in Slovenia.
